December 8, 2025Blood

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis reveals high relapse rates in patients with peripheral T-cell lymphoma, suggesting need for improved treatment strategies.

Over half of patients achieving complete response relapsed, highlighting ongoing risks after therapy.
The median progression-free survival for those relapsing was notably low at 9 months post-relapse.
Patients receiving Brentuximab vedotin as salvage therapy showed better post-relapse outcomes compared to conventional methods.
Long-term monitoring is crucial, as initial response duration did not significantly impact subsequent survival rates.

Shirouchi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals high relapse rates in patients with peripheral T-cell lymphoma, suggesting need for improved treatment strategies.

Over half of patients achieving complete response relapsed, highlighting ongoing risks after therapy.
The median progression-free survival for those relapsing was notably low at 9 months post-relapse.
Patients receiving Brentuximab vedotin as salvage therapy showed better post-relapse outcomes compared to conventional methods.
Long-term monitoring is crucial, as initial response duration did not significantly impact subsequent survival rates.

Shirouchi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark